The latest announcement is out from Qiagen ( (QGEN) ).
QIAGEN N.V. announced a manager’s transaction involving the grant of 5,990 Restricted Stock Units to Eva van Pelt, a member of its administrative or supervisory body. This transaction, linked to the exercise of share option programs, was conducted outside a trading venue and reflects the company’s ongoing commitment to aligning management incentives with shareholder interests.
More about Qiagen
QIAGEN N.V. operates in the biotechnology industry, focusing on providing sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. The company is known for its products that enable customers to gain valuable insights from biological samples.
YTD Price Performance: -13.75%
Average Trading Volume: 1,094,687
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $8.36B
For a thorough assessment of QGEN stock, go to TipRanks’ Stock Analysis page.